Lytgobi (futibatinib)

News alerts, weekly reports and conference planners

Company:

Otsuka

Drug class:

FGFR inhibitor

Related drugs:

FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1
FGFR2 fusion	Biliary Tract Cancer	FGFR2 fusion	Biliary Tract Cancer	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1
FGFR2 amplification	Gastric Cancer	FGFR2 amplification	Gastric Cancer	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2
FGFR1 amplification	Breast Cancer	FGFR1 amplification	Breast Cancer	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2
FGFR2 amplification	Breast Cancer	FGFR2 amplification	Breast Cancer	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2
FGFR3 mutation	Solid Tumor	FGFR3 mutation	Solid Tumor	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2
FGFR2 amplification	Triple Negative Breast Cancer	FGFR2 amplification	Triple Negative Breast Cancer	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2
FGFR2-BICC1 fusion	Cholangiocarcinoma	FGFR2-BICC1 fusion	Cholangiocarcinoma	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
FGFR2-SORBS1 fusion	Cholangiocarcinoma	FGFR2-SORBS1 fusion	Cholangiocarcinoma	futibatinib Resistant: C3 – Early Trials futibatinib Resistant : C3	futibatinib Resistant: C3 – Early Trials futibatinib Resistant : C3
TP53 mutation + FGFR2 rearrangement	Cholangiocarcinoma	TP53 mutation + FGFR2 rearrangement	Cholangiocarcinoma	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
TP53 mutation + FGFR2 fusion	Cholangiocarcinoma	TP53 mutation + FGFR2 fusion	Cholangiocarcinoma	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
PBRM1 mutation + FGFR2 fusion	Cholangiocarcinoma	PBRM1 mutation + FGFR2 fusion	Cholangiocarcinoma	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
PIK3CA mutation + FGFR2 rearrangement	Cholangiocarcinoma	PIK3CA mutation + FGFR2 rearrangement	Cholangiocarcinoma	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
PIK3CB mutation + FGFR2 rearrangement	Cholangiocarcinoma	PIK3CB mutation + FGFR2 rearrangement	Cholangiocarcinoma	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
PIK3R1 mutation + FGFR2 rearrangement	Cholangiocarcinoma	PIK3R1 mutation + FGFR2 rearrangement	Cholangiocarcinoma	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
BAP1 mutation + FGFR2 rearrangement	Cholangiocarcinoma	BAP1 mutation + FGFR2 rearrangement	Cholangiocarcinoma	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
BAP1 mutation + FGFR2 fusion	Cholangiocarcinoma	BAP1 mutation + FGFR2 fusion	Cholangiocarcinoma	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
IDH1 mutation + FGFR2 fusion	Cholangiocarcinoma	IDH1 mutation + FGFR2 fusion	Cholangiocarcinoma	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
IDH1 mutation + FGFR2 rearrangement	Cholangiocarcinoma	IDH1 mutation + FGFR2 rearrangement	Cholangiocarcinoma	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
FGFR1 mutation	Urothelial Cancer	FGFR1 mutation	Urothelial Cancer	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
FGFR1 rearrangement	Head and Neck Cancer	FGFR1 rearrangement	Head and Neck Cancer	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
FGFR1 fusion	CNS Tumor	FGFR1 fusion	CNS Tumor	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
FGFR1 rearrangement	CNS Tumor	FGFR1 rearrangement	CNS Tumor	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
FGFR3-TACC3 fusion	Gastric Cancer	FGFR3-TACC3 fusion	Gastric Cancer	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
FGFR2 mutation	Solid Tumor	FGFR2 mutation	Solid Tumor	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
FGFR1 mutation	Solid Tumor	FGFR1 mutation	Solid Tumor	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
FGFR4 overexpression	Breast Cancer	FGFR4 overexpression	Breast Cancer	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
FGFR3 overexpression	Breast Cancer	FGFR3 overexpression	Breast Cancer	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
FGFR2 overexpression	Breast Cancer	FGFR2 overexpression	Breast Cancer	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3

Lytgobi (futibatinib)

Associations
(52)

Associations
(52)

Lytgobi (futibatinib)

Associations(52)

Associations(52)

Associations
(52)

Associations
(52)